Users Coming Off Weight-Loss Injections Regain Pounds Far More Rapidly Compared to Those on Conventional Diets

New research reveals that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise regimens.

Published data in a leading medical journal demonstrates that while overweight individuals can lose about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.

"People purchasing such medications should be informed of the danger of fast rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.

Such speed of regain implies a reversion to original weight within about one and a half years.

Analyzing Approaches

The research, which reviewed dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills.

The team point out that individuals who shed pounds through lifestyle changes alone usually have a less rapid creep back—approximately 0.1 kg a month—after stopping.

The Reason for the Fast Rebound

Doctors propose the way of the drugs is key to understanding the heightened regain.

GLP-1 drugs imitate a natural hormone called GLP-1, which moderates appetite.

"Artificially providing GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.

"Stopping of this medication leads to hunger is unsuppressed, making binge eating much more probable."

A Lifelong Issue?

Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.

A number of clinicians say that, given the likelihood of relapse, the therapy is often life-long.

This perspective is reinforced by pharmaceutical companies, who say that the findings "emphasize the long-term character of obesity," similar to managing diseases like diabetes.

Patient Testimonies

People who have come off the jabs explain a intense return of hunger.

"I experienced a switch activating and I was suddenly ravenous," recalled one woman.

This challenge is compounded if patients have not established sustainable dietary or behavioural modifications during therapy.

Widespread Interest

Recent estimates indicate that millions of people in the UK have used these injections in the past year, with desire being substantial.

• Adoption is greater among women than males.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion obtain the medications through private healthcare rather than the NHS.

In conclusion, experts emphasize that while these medications are potent agents for shedding pounds, they are not a permanent fix and lasting health benefits hinges on ongoing behavioural changes.